Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02250222 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02250222 is a Phase 1 study that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT02250222, a Phase 1 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
Ligand Pharmaceuticals Incorporated is developing LGD-6972, a novel, orally-bioavailable addition to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The mechanism of action of LGD-6972 is to reduce the excess liver glucose production characteristic of type 2 diabetes mellitus that is a major contributor to hyperglycemia. This clinical trial will evaluate the safety and tolerability of escalating doses LGD-6972 administered daily over 2 weeks in both healthy subjects and subjects with type 2 diabetes mellitus.
Interventions
- DRUG LGD-6972
- DRUG Placebo (Captisol ®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02250222
The ClinicalTrials.gov registry entry for NCT02250222 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ligand Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LGD-6972 is the first listed.
NCT02250222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02250222 about?
NCT02250222 is a clinical study titled "Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus". Ligand Pharmaceuticals Incorporated is developing LGD-6972, a novel, orally-bioavailable addition to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The mechanism of action of LGD-6972 is to reduce the excess liver glucose production characteristic of type 2 di...
What is the current status of trial NCT02250222?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2014-10. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02250222?
The interventions under investigation include: LGD-6972 (DRUG), Placebo (Captisol ®) (DRUG).
Who is sponsoring clinical trial NCT02250222?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.